Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Atezolizumab + Cobimetinib + Vemurafenib & Melanoma (cutaneous) (BRAF m), FDA approved atezolizumab + cobimetinib + vemurafenib for unresectable or metastatic Melanoma (cutaneous) (BRAF m); EMA did not approve it, the use of this combination is off‑label (1, 2).
The randomized clinical phase III treatment trial, identified as NCT02908672, demonstrated that incorporating atezolizumab into the targeted therapy regimen with vemurafenib and cobimetinib was both safe and tolerable. Moreover, it significantly enhanced progression-free survival in patients with the BRAF^V600 mutatio…